Alliance Fiber Optic (Nasdaq:AFOP-Free Report) recently became a Zacks Rank #1 (Strong Buy), in fact, it was Zacks Rank #2 (Buy) stock on April 5, but the rank moved higher on April 8th. Today it is the Bull of the Day.
Back in July I wrote about my "Best Tech Stocks For 2nd Half of 2013" and I discussed the idea of more devices coming soon and how they will create demand for more bandwidth. Since then, there have been several publications stating the same thing. What the others were missing is the idea that those devices will all drive the need for more bandwidth from the carriers.
AFOP designs and manufactures components, modules, and subsystems that empower dynamic optical network, and facilitates the migration of fiber optics from the long haul through the last mile. That is all industry jargon for they make a fiber optic connection to your business or home a reality.
Over the last four quarters, AFOP has met the Zacks Consensus Estimate three times. The most recently reported quarter saw a miss of $0.07 or 21%. That large miss sent the stock tumbling 23% in the session following the earnings release.
Prior to that miss, the stock traded 7% - 8% higher in each of the quarters with an earnings meet. Clearly, the market was pleased with earnings meets given that quarterly revenue is still pretty small and around $20M or so.
Talisman Energy (NYSE:TLM-Free Report) has tumbled about 7% so far year to date. That doesn't seem so bad, given the recent environment, but a quick look at the price and consensus chart shows why this stock is the Bear of the Day.
Recently the price of oil has moved higher. This comes as many question the footing the economy is on and intensifying geo-political concerns in
Ukraine. Along with oil moving higher we have also seen strength in the price of natural gas despite relatively great weather across most of the
Of course the weather has a way of changing, but as we move into the summer months, the pattern of the price of natural gas coming down might not be seen this year. Some experts are pointing to the situation in
Ukraine, but others are talking about increases in inflation.
Talisman Energy is an oil and gas company. It holds interests in various oil and gas properties located in
Papua New Guinea, the
Colombia and the Kurdistan Region of
Iraq, as well as in
Australia/Timor-Leste. The company was founded in 1925 and is headquartered in
over the last four quarters, TLM has missed the Zacks Consensus Estimate four times. The most recently reported quarter saw a miss of $0.17 or 340%.
Keep an Eye on These 3 Biotech Stocks
The biotech industry, which reported robust growth last year and was off to a strong start early in 2014, witnessed a major sell-off in the last couple of months. The NYSE ARCA Biotech Index (^BTK) and NASDAQ Biotechnology Index (^NBI) have declined more than 7.8% and 7.9%, respectively, in the last 2 months.
The sell-off was triggered by lawmakers issuing a letter to Gilead Sciences Inc. (Nasdaq:GILD-Free Report) questioning the pricing of its recently approved hepatitis C virus (HCV) treatment, Sovaldi. The drug, priced at $84,000 for an 84-day treatment (12 weeks), came under the scanner for being way too expensive. This led to further speculations about lawmakers putting pressure on biotech companies to cut their prices.
It is however worth noting that this sell-off was more due to a change in sentiment rather than a shift in industry fundamentals. Recently, a trend reversal has also been noticed with the NYSE ARCA Biotech Index and NASDAQ Biotechnology recovering approximately 4.6% and 5.5%, respectively last week. Investor expectations from biotech companies are building up as the Q1 earnings season kicks in. Several major biotech companies are expected to report their first quarter earnings this week.
The currently subdued prices provide investors an attractive entry point. In fact, it is a good idea to zero in on a handful of biotech stocks that are poised to beat earnings estimates this quarter. An earnings beat should help these stocks regain investor confidence and send share prices higher.
How to Pick?
Given the large number of industry participants, pinpointing stocks that have the potential to beat estimates could appear to be a daunting task. But our proprietary methodology makes it fairly simple. One way to narrow down the list of choices this earnings season is by looking at stocks that have the combination of a favorable Zacks Rank – Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) – and a positive Zacks Earnings ESP (Expected Surprise Prediction).
Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising in their next earnings announcement. It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate.
Our research shows that for stocks with this combination, the chance of a positive earnings surprise is as high as 70%.
Below are three biotech stocks we believe are best positioned to stand out this earnings season.
Gilead, based in Foster City, CA, is a Zacks Rank #3 (Hold) stock with an Earnings ESP of +22.67%. The Zacks Consensus Estimate for the first quarter is 75 cents.
Gilead is focused on the discovery, development and commercialization of drugs for human immunodeficiency virus (HIV), liver diseases such as hepatitis B virus (HBV) and HCV, respiratory, oncology /inflammation and cardiovascular related diseases. The company has delivered positive earnings surprises in two of the last four quarters.
Key growth drivers – Viread, Complera and Stribild – should continue with their strong performance in the first quarter. However, the main focus will be on Sovaldi which has blockbuster potential – this is the first full quarter for Sovaldi which was launched in Dec 2013.
Gilead is scheduled to announce its first quarter 2014 financial results after the closing bell on Apr 22.
Biogen Idec Inc. (Nasdaq:BIIB-Free Report) is a Zacks Rank #1 stock with an Earnings ESP of +8.14%. The Zacks Consensus Estimate for the first quarter stands at $2.58. The company has a solid track record of delivering positive surprises with an average beat of 15.62% in the last four quarters. The company is expected to beat expectations in the first quarter as well.
The Cambridge, MA-based biotechnology company is engaged in the development and commercialization of therapies targeting autoimmune disorders including multiple sclerosis, neurodegenerative diseases and hemophilia.
Tecfidera should continue performing well in the first quarter. Additionally, Tysabri and Avonex should remain strong contributors to the top line.
Biogen will be reporting first quarter 2014 results before the markets opens on Apr 23.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN-Free Report), based in
, is focused on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. The stock carries a Zacks Rank #2, with an Earnings ESP of +10.68%. The Zacks Consensus Estimate for the first quarter is $1.03.
The company has registered a positive earnings surprise in each of the last four quarters with an average beat of 8.07%. The company is expected to surpass expectations on the back of its sole marketed product, Soliris, and also aided by lower taxes.
Alexion is expected to report first quarter 2014 earnings on Apr 24 before the opening bell.
Despite the pressure on biotechs this quarter due to the recent sell-off, investing in this sector will be rewarding for those investors who are willing to be patient. While a number of biotech companies are facing challenges in the form of increasing competition, they are nevertheless looking for better strategies to emerge as winners.
Biotech companies have been attracting a lot of attention with a lot of merger and acquisition activity going on. A sneak peek at the space for some outperformers, backed by a solid Zacks Rank and a positive Zacks Earnings ESP, could be a great idea for investors to gain from this earnings season.
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blogprovides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time!Register for your free subscription to Profit from the Pros.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.